Last reviewed · How we verify
LEVALLORPHAN TARTRATE
LEVALLORPHAN TARTRATE is a drug. It is currently FDA-approved (first approved 1982).
Levallorphan tartrate is a small molecule that acts as a mu opioid receptor antagonist. It belongs to the class of antagonists and is also known by the synonyms levallorphan tartrate and lorfan.
At a glance
| Generic name | LEVALLORPHAN TARTRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEVALLORPHAN TARTRATE CI brief — competitive landscape report
- LEVALLORPHAN TARTRATE updates RSS · CI watch RSS
Frequently asked questions about LEVALLORPHAN TARTRATE
What is LEVALLORPHAN TARTRATE?
LEVALLORPHAN TARTRATE is a Small molecule drug.
When was LEVALLORPHAN TARTRATE approved?
LEVALLORPHAN TARTRATE was first approved on 1982.
What development phase is LEVALLORPHAN TARTRATE in?
LEVALLORPHAN TARTRATE is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing